Skip to content

Oxiconazole Nitrate

FDA-approved product (cream, topical), marketed as Oxiconazole Nitrate, Oxistat.

Registered studies
4
Lab records
1
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Oxiconazole Nitrate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Tinea
  • Tinea pedis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Imidazole and triazole derivatives; Imidazole derivatives
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC D01AC11; WHO ATC G01AF17

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli10.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae5.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

4registered studies name this medicine, for any condition. See them below.

Experimental

  • K. pneumoniae: measured active in 0 of 1 lab record
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Oxiconazole Nitrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparative Efficacy of Topical Oxiconazole Cream (1%) Versus Topical Clotrimazole Cream (1%) in the Treatment of Tinea CrurisAbstract

    NCT07441005 · start 2025-05-15

    Registered record
    Registry ID
    NCT07441005
    Conditions
    Tinea Cruris
    Interventions
    Topical Oxiconazole cream; Topical Clotrimazole cream
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2025-05-15
    Completion
    2025-10-15
    Enrolment
    386

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTinea Cruris
    InterventionTopical Oxiconazole cream; Topical Clotrimazole cream
    PhaseEarly phase 1
    Registry statusCompleted
  • Comparative Study of Topical Oxiconazole 1% Cream Versus Clotrimazole 1% Cream in the Treatment of Dermatophytosis

    NCT07718685 · start 2025-01-01

    Registered record
    Registry ID
    NCT07718685
    Conditions
    Dermatophytoses
    Interventions
    Oxiconazole Nitrate Cream; Clotrimazole Cream
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-01-01
    Completion
    2025-06-30
    Enrolment
    164

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermatophytoses
    InterventionOxiconazole Nitrate Cream; Clotrimazole Cream
    PhaseNot applicable
    Registry statusCompleted
  • Clinical Assessment of Oxiconazole Nitrate Solid Lipid Nanoparticles Loaded Gel

    NCT03823040 · start 2018-07-16

    Registered record
    Registry ID
    NCT03823040
    Conditions
    Tinea
    Interventions
    Oxiconazole Nitrate Cream 1%; Oxiconazole nitrate SLNs loaded gel.
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-07-16
    Completion
    2018-12-30
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTinea
    InterventionOxiconazole Nitrate Cream 1%; Oxiconazole nitrate SLNs loaded gel.
    PhasePhase 1
    Registry statusCompleted
  • A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis

    NCT01519752 · start 2011-11

    Registered record
    Registry ID
    NCT01519752
    Conditions
    Tinea Pedis
    Interventions
    Oxiconazole Nitrate Cream 1%; Oxiconazole Nitrate Cream 1% (Oxistat®); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-11
    Completion
    2012-11
    Enrolment
    661

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTinea Pedis
    InterventionOxiconazole Nitrate Cream 1%; Oxiconazole Nitrate Cream 1% (Oxistat®); Placebo
    PhasePhase 1
    Registry statusCompleted